Small Molecule Drug Development with Multi-Scale PAT
Zachary Dance of Merck & Co., Inc. describes leveraging multi-scale PAT capabilities to enhance small molecule development.
Programöversikt
- Ability to influence route selection
- Mechanistic understanding
- Assess process scalability and robustness
- Efficiency through real time monitoring and control
Zachary Dance describes how Merck's small molecule R&D group leverages Process Analytical Technology (PAT) to collect data often considered inaccessible. Data-Rich Experimentation (DRE) is one of the primary strategic areas of focus within Merck Research Laboratories, Process Research and Development. The objective is to significantly enhance the ability to generate and analyze data with the efficiency and productivity needed to achieve efficient drug invention, development, and commercialization. One of the key components of the DRE strategy is enabling widespread use of Process Analytical Technology (PAT).
Dr. Dance presents the current state of Merck Research Laboratories’ small molecule PAT toolset. He discusses the integration of modern instrumentation from lab to pilot scale, and includes select examples where PAT was utilized to enhance process understanding.
Join the hundreds of researchers who already viewed this presentation.
About the Presenter
Dr. Zachary Dance
Merck & Co, Inc.
After receiving his Ph.D. in Physical Organic Chemistry from Northwestern University, Dr. Dance joined Merck’s Center for Materials Science and Engineering. Since then, he has developed expertise in solid state characterization and PAT specifically in materials of pharmaceutical interest. Most recently, Dr. Dance has led the Merck Research Labs Small Molecule PAT team. He has experience supporting development at all scales, troubleshooting, process optimization, and experimental design related to synthetic reaction understanding and physicochemical properties of APIs and excipients, as well as contributing to multiple patent and regulatory filings.
